JCO Impact Factor

JCO's IF has more than doubled since 2012, growing from ~18 to 41.9. That trajectory reflects the explosion of clinical oncology trials, the rise of immunotherapy and targeted therapy publications, and JCO's increasing selectivity. The slight 2024 dip from the 2022 peak mirrors patterns across high-IF journals as post-pandemic citation dynamics normalize.

JCO covers the full spectrum of clinical oncology. The journal publishes original research articles (primarily phase II/III clinical trials), reviews, editorials, special articles, and ASCO clinical practice guidelines. The editorial board prioritizes studies that directly inform treatment decisions, randomized trials with survival endpoints, large prospective cohort studies, and meta-analyses that change clinical practice. JCO also publishes translational research when it has clear clinical implications, particularly biomarker-driven studies that inform patient selection for therapies. ASCO guidelines published in JCO are among the most-cited items in oncology.

JCO's review process is faster than many journals at its level. Most desk rejections come within 1-2 weeks. If your paper enters peer review, expect a first decision within 6-8 weeks. The journal uses 2-3 reviewers, and the editorial board is responsive during revision cycles.

JCO's IF (41.9) is higher than Lancet Oncology (35.9) and comparable to Cancer Cell (44.5), though the journals serve different purposes. JCO is purely clinical oncology. Cancer Cell is cancer biology. The comparison that matters for clinical oncology researchers is JCO vs Lancet Oncology.

JCO publishes more papers per year than Lancet Oncology and has a broader scope within clinical oncology. The 41.9 IF reflects this volume and the high citation rate of clinical oncology trials. Papers that change treatment guidelines are cited hundreds of times.

Submit if:

• the study presents clinical oncology evidence that informs treatment decisions
• phase III trial results, large retrospective analyses, or guideline-informing data
• the ASCO community is your primary audience
• the evidence level matches JCO's selectivity (~10% acceptance)

Think twice if:

• the paper is cancer biology without clinical endpoints (Cancer Cell, Nature Cancer)
• Lancet Oncology's global emphasis and Lancet editorial process is a better fit
• the clinical scope is narrow enough for a subspecialty oncology journal
• Annals of Oncology would reach European oncologists more effectively

A JCO submission readiness check can help assess whether the clinical evidence meets JCO's editorial threshold.

JCO's Scopus profile reinforces the JCR picture. The 2024 CiteScore is 38.9 and the SJR is 11.205, placing JCO at rank 9 out of 415 oncology journals. The SNIP of 5.983 shows that JCO's citation performance isn't inflated by oncology's naturally high citation density, it's genuinely exceptional even after field normalization. For institutions that weight Scopus-style indicators, these numbers confirm JCO's position as one of the strongest clinical oncology venues in the world.

The JCI of 6.68 places JCO in elite territory. For clinical oncologists, JCO is the default citation target for trial results. A practice-changing phase 3 trial published in JCO gets cited hundreds of times within 2-3 years.

JCO's editorial culture is shaped by ASCO (American Society of Clinical Oncology):

1. Practice-changing potential. JCO publishes results that directly inform treatment decisions. Reviewers ask: "Would an oncologist change what they do based on this paper?" If the answer is "probably not yet," the paper likely belongs in a specialty oncology journal.
2. Rigorous trial design. JCO is the gold standard for phase 2-3 clinical trial results. Reviewers scrutinize randomization, endpoints, sample size justification, and intent-to-treat analysis with unusual thoroughness.
3. Biomarker and correlative science. Pure molecular biology without clinical context doesn't fit JCO. But trial papers that include biomarker correlatives (predictive markers, resistance mechanisms) are favored over those that don't.
4. Real-world evidence standards. JCO increasingly publishes observational and real-world evidence studies, but holds them to high methodological standards (STROBE compliance, sensitivity analyses, clear limitations).
5. Patient-reported outcomes. Reviewers notice when quality-of-life data is missing. Including PRO data strengthens any JCO submission.

A JCO submission readiness check can assess whether your trial results or oncology study meets JCO's clinical impact threshold.

The oncology journal landscape is unusually crowded at the top. There are more IF 30+ oncology journals than in almost any other medical specialty. Understanding where JCO sits (and what it does differently from journals with similar or higher IFs) matters for submission strategy.

JCO's JCI of 6.68 confirms it's not just riding oncology's naturally high citation rates, it's genuinely exceptional after field normalization. The journals above JCO in raw IF are either review-only (CA, Nature Reviews) or serve different editorial missions (Annals of Oncology is ESMO's flagship the way JCO is ASCO's). For original clinical oncology research, JCO and Lancet Oncology are the two realistic targets, with Annals of Oncology as the European alternative.

JCO papers aren't created equal when it comes to citation impact. The 41.9 IF is an average across all article types, but the spread between a guideline-changing phase 3 trial and a retrospective cohort study is enormous. Here's what actually predicts whether a JCO paper gets cited heavily.

The single strongest citation predictor is guideline impact. When a JCO paper leads to an ASCO or NCCN guideline update, every oncologist writing a protocol, grant, or review paper cites it. Phase 3 trials with overall survival endpoints in common cancers that include biomarker analysis are the papers that hit 200+ citations within two years.

Papers without biomarker correlatives are increasingly at a disadvantage. JCO's editorial board has pushed hard for translational science integration, and reviewers now routinely ask why a clinical trial paper doesn't include predictive marker data. Including even exploratory biomarker analysis strengthens both the acceptance odds and the long-term citation trajectory.

A JCO submission readiness check can evaluate whether your oncology study has the clinical impact elements that JCO reviewers prioritize.

Most people think of JCO as a clinical trials journal. It is, but the papers that drive the biggest citation numbers are often something else entirely: ASCO Clinical Practice Guidelines, Provisional Clinical Opinions, and Quality of Care articles.

ASCO guidelines published in JCO are among the most-cited documents in all of oncology. For mid-career oncologists, joining an ASCO guideline panel isn't just service work, it's a path to JCO authorship that doesn't require running your own phase 3 trial. Quality of Care articles are an underused submission category. JCO publishes research on cancer care delivery, health equity, and value-based oncology that doesn't need to be a randomized trial. If your work addresses how oncology care is delivered rather than what treatment works, this category is worth exploring.

In our pre-submission review work with oncology manuscripts targeting JCO, three patterns generate the most consistent desk-rejection outcomes.

Biomarker-free phase 2 and 3 trial reports. JCO's editorial board has documented its push for translational science integration. Reviewers now routinely flag trials that enroll patients, report efficacy and toxicity endpoints, and submit without any predictive biomarker data, even exploratory marker analysis. The framing this triggers: "Why doesn't this trial tell us which patients benefit?" A phase 2 single-arm trial showing 42% objective response rate in unselected patients is technically publication-worthy data, but JCO editors increasingly ask whether the manuscript advances patient selection or just documents a response rate that will require a larger trial to confirm. Including even preliminary biomarker analysis from a defined patient subset, or pre-specifying why marker-unselected enrollment was the right design choice, is the difference between a manuscript that clears the desk and one that doesn't.

Retrospective analyses confirming established clinical rankings. JCO accepts retrospective real-world evidence studies, but the bar is "practice-changing real-world data," not "large dataset confirming what randomized trials already established." A retrospective analysis of claims data showing that Drug A has better adherence than Drug B among Medicare patients is potentially publishable. A retrospective analysis of the same population showing Drug A has similar survival to Drug B when the RCT already showed this is not. The distinction is whether the retrospective data resolves a clinical uncertainty or merely reproduces a known result in a real-world sample. Reviewers ask: "Would an oncologist change anything based on this?"

Mechanistic manuscripts misrouted to a clinical journal. JCO is ASCO's clinical flagship. Papers that are primarily translational, a new immune evasion mechanism in NSCLC, a cell-line study of resistance pathways, a mouse model of combination therapy, will be returned, regardless of oncological relevance. The ASCO family directs these papers to Cancer Research or Cancer Cell. If the manuscript's primary contribution is a biological mechanism without a clinical dataset, it needs a different venue before reaching JCO. A JCO submission readiness check can confirm whether the manuscript's evidence package meets JCO's clinical bar before you commit to the submission.